Boston Children’s Hospital (BCH) invests heavily in research because science saves lives. They are focused on accelerating new treatments for devastating diseases as our discoveries translate from the laboratory bench to the patient’s bedside, where they have been improving the health of children and adults since 1869.
The research enterprise at Boston Children’s Hospital (BCH)—comprising more than 3,000 researchers and representing annual expenditures of greater than $375 million—is the world’s largest at a pediatric center. Their work is fueled by a deep understanding of disease coupled with world-class discovery platforms, including genetics and genomics, gene editing, bioinformatics, proteomics, bioengineering, image analysis, multiple animal models, biobanks and disease-specific stem cell lines. The hospital has special expertise in rare disease discovery and see large, highly diverse patient populations.
“Members of our research community include nine members of the National Academy of Sciences, 18 members of the National Academy of Medicine, 16 Howard Hughes Medical Institute Investigators and alumni, and eight Lasker Award recipients,” said August Cervini, Vice President, Research Administration at BCH. “In total, our research community publishes more peer-reviewed research in top scientific journals than the next 20 children’s hospitals combined — more than 3,000 annually.”
One of the most exciting endeavors in science at Boston Children’s Hospital is around stem cell research. Stem cell clinical trials underway at Boston Children’s include a trial that will be among the first to differentiate stem cells into tissues and transplant them into diseased organs. In another trial, a patient has already been treated (link is external) with retinal cells for macular degeneration of the eye, derived from induced pluripotent stem cells. A separate trial hopes to turn pluripotent cells into natural killer cells that could be used to fight tumors (link is external). “Overall the hope at BCH is to have the ability to transfuse stem-cell-derived platelets (link is external) into patients who cannot receive normal platelet units because they develop antibodies against them,” explained Mr. Cervini.
BCH’s investigators—as well as researcher across the country—are on the precipice of discovering new therapies for deadly diseases and continuous support of medical research will benefit Americans for generations to come. Our national investment in research is also a key economic driver at the local, state, and federal level as we closely watch how other nations—especially China—are increasing their commitment to research.
“Boston Children’s relationship with Research!America is critically important to educating Congress about how essential it is to invest in the nation’s burgeoning biomedical science environment,” said Mr. Cervini.
“Since its founding in the late 80s, Research!America has played an incredible important role in mobilizing and leveraging the funding, advocacy and input of the federal government, academia, industry and philanthropy to meet our national goal of improving human health,” he added.
Boston Children’s Hospital is proud to be listed as a contributing member of one of our nation’s most effective advocacy organizations. For more information, visit www.childrenshospital.org.